Skip to main content

Articles

Page 34 of 76

  1. Triple negative breast cancer (TNBC) is an incurable disease where novel therapeutic strategies are needed. Proteolysis targeting chimeric (PROTAC) are novel compounds that promote protein degradation by bindi...

    Authors: María del Mar Noblejas-López, Cristina Nieto-Jimenez, Miguel Burgos, Mónica Gómez-Juárez, Juan Carlos Montero, Azucena Esparís-Ogando, Atanasio Pandiella, Eva M. Galán-Moya and Alberto Ocaña
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:383
  2. Ovarian carcinomas are the deadliest gynecological malignancies owing to their high rate of recurrence and high resistance to platinum-based chemotherapy. Recent studies have shown platinum-dependent enrichmen...

    Authors: Syed S. Islam and Abdelilah Aboussekhra
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:382
  3. High rates of recurrence and metastasis are the major cause of the poor outcomes for patients with lung cancer. In previous research, we have demonstrated that Tac2-N promotes tumor growth by suppressing p53 s...

    Authors: Xianglin Hao, Li-yun Gao, Ning Zhang, Hongqiang Chen, Xiao Jiang, Wenbin Liu, Lin Ao, Jia Cao, Fei Han and Jinyi Liu
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:319
  4. Anti-angiogenesis remains an attractive strategy for cancer therapy. Some anti-angiogenic reagents have bell-shape dose-response curves with higher than the effective doses yielding lower anti-angiogenic effec...

    Authors: Jialiang Hu, Wenjing Wang, Chen Liu, Mengwei Li, Edouard Nice and Hanmei Xu
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:381

    The Retraction Note to this article has been published in Journal of Experimental & Clinical Cancer Research 2020 39:35

  5. Accumulating evidence demonstrates the oncogenic roles of lncRNA (long non-coding RNA) molecules in a wide variety of cancer types including glioma. Equally important, However, tumorigenic functions of lncRNA ...

    Authors: Zhenzhe Li, Jixing Zhang, Hongshan Zheng, Chenlong Li, Jinsheng Xiong, Weiliang Wang, Hongbo Bao, Hua Jin and Peng Liang
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:380
  6. TP53 is one of the most frequently mutated genes among all cancer types, and TP53 mutants occur more than 60% in colorectal cancer (CRC). Among all mutants, there are three hot spots, including p53-R175H, p53-...

    Authors: Yuechao Zhao, Yiran Li, Jie Sheng, Fan Wu, Kai Li, Rong Huang, Xiaojuan Wang, Tao Jiao, Xin Guan, Yan Lu, Xiao Chen, Zhiwen Luo, Yanchi Zhou, Hanjie Hu, Wenjie Liu, Boyu Du…
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:379
  7. Cripto-1 (CR-1) has been reported to be involved in the development of several human cancers. The potential role of CR-1 in clear cell renal cell carcinoma (ccRCC) is still not clear.

    Authors: Yi-Jun Xue, Song-Ning Chen, Wei-Guang Chen, Geng-Qing Wu, Yun-Feng Liao, Jian-Bin Xu, Hao Tang, Shui-Hua Yang, Shui-Yong He, Yun-Fei Luo, Zhi-Hui Wu and Hai-Wen Huang
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:378
  8. Cardamonin, a chalcone isolated from Alpiniae katsumadai, has anti-inflammatory and anti-tumor activities. However, the molecular mechanism by which cardamonin inhibits breast cancer progression largely remains t...

    Authors: Jinmei Jin, Shuiping Qiu, Ping Wang, Xiaohui Liang, Fei Huang, Hui Wu, Beibei Zhang, Weidong Zhang, Xinhui Tian, Ren Xu, Hailian Shi and Xiaojun Wu
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:377
  9. Metformin has been reported to function as the anti-tumor inhibiting the growth of different types of cancers, including bladder cancer. But there are few reports on the roles of Yap1, the key molecule of Hipp...

    Authors: Yanju Wu, Qianqian Zheng, Yan Li, Guang Wang, Shuting Gao, Xiaodong Zhang, Xu Yan, Xinwen Zhang, Jisheng Xie, Yuanyuan Wang, Xun Sun, Xin Meng, Bo Yin and Biao Wang
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:376
  10. An increasing number of studies have demonstrated that long non-coding RNAs (lncRNAs) play pivotal roles in cancer onset and development. LncRNA AFAP1-AS1 has been validated to be abnormally upregulated and pl...

    Authors: Deyao Shi, Fashuai Wu, Shidai Mu, Binwu Hu, Binlong Zhong, Feng Gao, Xiangcheng Qing, Jianxiang Liu, Zhicai Zhang and Zengwu Shao
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:375

    The Correction to this article has been published in Journal of Experimental & Clinical Cancer Research 2020 39:72

  11. In the original publication of this article [1], there is an error in Fig. 4A.

    Authors: Jia Wei, Ling Ma, Yi-Hui Lai, Ruijie Zhang, Huameng Li, Chenglong Li and Jiayuh Lin
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:374

    The original article was published in Journal of Experimental & Clinical Cancer Research 2019 38:63

  12. An increasing number of anticancer agents has been proposed in recent years with the attempt to overcome treatment-resistant cancer cells and particularly cancer stem cells (CSC), the major culprits for tumour...

    Authors: Isabella Orienti, Valentina Salvati, Giovanni Sette, Massimo Zucchetti, Lucilla Bongiorno-Borbone, Angelo Peschiaroli, Lello Zolla, Federica Francescangeli, Mariella Ferrari, Cristina Matteo, Ezia Bello, Antonio Di Virgilio, Mario Falchi, Maria Laura De Angelis, Marta Baiocchi, Gerry Melino…
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:373
  13. The interaction between tumor cells and their immunosuppressive microenvironment promotes tumor progression and drug resistance. Thus, simultaneously targeting tumor cells and stromal cells is expected to have...

    Authors: Xia Peng, Pengcong Hou, Yi Chen, Yang Dai, Yinchun Ji, Yanyan Shen, Yi Su, Bo Liu, Yueliang Wang, Deqiao Sun, Yuchen Jiang, Chuantao Zha, Zuoquan Xie, Jian Ding, Meiyu Geng and Jing Ai
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:372
  14. Arachidonic acid (AA) metabolic enzymes including cyclooxygenase-2 (COX-2), microsomal prostaglandin E synthase-1 (mPGES-1) and cytochrome P450 (CYP) 4A11 play important roles in glioma angiogenesis. Thus, the...

    Authors: Chenlong Wang, Yaxin Chen, Yang Wang, Xiaoxiao Liu, Yanzhuo Liu, Ying Li, Honglei Chen, Chengpeng Fan, Dongfang Wu and Jing Yang
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:371
  15. Topoisomerase inhibitors (TI) can inhibit cell proliferation by preventing DNA replication, stimulating DNA damage and inducing cell cycle arrest. Although these agents have been commonly used in the chemother...

    Authors: Jiafei Liu, Like Qu, Lin Meng and Chengchao Shou
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:370
  16. Esophageal squamous cell carcinoma (ESCC) is one of the most common cancers worldwide, which lacks effective biomarkers for prognosis. Therefore, it is urgent to explore new potential molecular markers to disc...

    Authors: Yan Liu, Yingru Zhi, Haizhu Song, Mingzhu Zong, Jun Yi, Guoxin Mao, Longbang Chen and Guichun Huang
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:369
  17. Survivin (also named BIRC5) is a well-known cancer therapeutic target. Since its discovery more than two decades ago, the use of survivin as a target for cancer therapeutics has remained a central goal of surv...

    Authors: Fengzhi Li, Ieman Aljahdali and Xiang Ling
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:368
  18. In the publication of this article [1], there is an error in Fig. 5C (panel 4, group of InmiR-26a + silinc01296 in SW620). The revised Fig. 5 which includes 5C has now been included in this correction.

    Authors: Bing Liu, Shimeng Pan, Yang Xiao, Qianqian Liu, Jingchao Xu and Li Jia
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:367

    The original article was published in Journal of Experimental & Clinical Cancer Research 2018 37:316

  19. The epithelial-to-mesenchymal transition (EMT) has been linked to the regulation of glioma progression. However, the underlying signaling mechanisms that regulate EMT are poorly understood.

    Authors: Erbao Bian, Xueran Chen, Yadi Xu, Xinghu Ji, Meng Cheng, Hongliang Wang, Zhiyou Fang and Bing Zhao
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:366
  20. The lncRNA LINC00460 plays crucial roles in several epithelial cancers, although its mechanisms of action differ greatly in different cellular contexts. In this study, we aimed to determine the potential clini...

    Authors: Yingying Jiang, Wei Cao, Kun Wu, Xing Qin, Xiaoning Wang, Yan Li, Binbin Yu, Zhen Zhang, Xu Wang, Ming Yan, Qin Xu, Jianjun Zhang and Wantao Chen
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:365
  21. Microsatellite unstable colorectal cancers (MSI+ CRCs) expressing PD-L1, respond to anti-PD-1 or anti-PD-L1 checkpoint blockade, whereas microsatellite-stable tumors do not respond the same. Our aim was to exa...

    Authors: Apostolos Zaravinos, Constantinos Roufas, Majdi Nagara, Beatriz de Lucas Moreno, Maria Oblovatskaya, Christodoulos Efstathiades, Christos Dimopoulos and Georgios D. Ayiomamitis
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:364
  22. In order to develop a new immunotherapeutic agent targeting metastatic breast cancers, we chose to utilize autocatalytic feature of the membrane serine protease Prss14/ST14, a specific prognosis marker for ER ...

    Authors: Ki Yeon Kim, Minsang Yoon, Youngkyung Cho, Kwang-Hoon Lee, Sora Park, Se-ra Lee, So-Young Choi, Deokjae Lee, Chansik Yang, Eun Hye Cho, Sangjun Davie Jeon, Seok-Hyung Kim, Chungho Kim and Moon Gyo Kim
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:363
  23. Tumor targeting small molecular inhibitors are the most popular treatments for many malignant diseases, including cancer. However, the lower clinical response and drug resistance still limit their clinical eff...

    Authors: Xiaoge Gao, Pin Jiang, Qian Zhang, Qian Liu, Shuangshuang Jiang, Ling Liu, Maomao Guo, Qian Cheng, Junnian Zheng and Hong Yao
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:362

    The Correction to this article has been published in Journal of Experimental & Clinical Cancer Research 2023 42:87

  24. Triple Negative Breast cancer (TNBC) is incurable cancer with higher rates of relapse and shorter overall survival compared with other subtypes of breast cancer. Cellular retinoic acid binding protein 2 (CRABP...

    Authors: Xuefei Feng, Miao Zhang, Bo Wang, Can Zhou, Yudong Mu, Juan Li, Xiaoxu Liu, Yaochun Wang, Zhangjun Song and Peijun Liu
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:361
  25. A major limitation in the treatment for malignant mesothelioma is related to serious side effects caused by chemotherapeutics and to the development of cancer-resistance. Advances in cancer therapies have been...

    Authors: Francesco Di Meo, Stefania Filosa, Michele Madonna, Gerarda Giello, Alba Di Pardo, Vittorio Maglione, Alfonso Baldi and Stefania Crispi
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:360
  26. Epidemiological observations have demonstrated that ambient fine particulate matter with dp < 2.5 μm (PM2.5) as the major factor responsible for the increasing incidence of lung cancer in never-smokers. However, ...

    Authors: Ming-Yue Li, Li-Zhong Liu, Wende Li, Calvin S. H. Ng, Yi Liu, Angel W. Y. Kong, Zhili Zhao, Shanshan Wang, Haolong Qi, Hao Jia, Shucai Yang, Jing Du, Xiang Long, Rocky L. K. Ho, Ernest C. W. Chak, Innes Y. P. Wan…
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:359
  27. MicroRNAs (miRNAs) play crucial roles in tumor initiation and development. Previously, we indicated that miR-504 is downregulated and suppresses tumor proliferation in glioblastoma (GBM). However, the regulati...

    Authors: Qiang Liu, Yanlei Guan, Zhenhang Li, Yao Wang, Yu Liu, Run Cui and Yunjie Wang
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:358
  28. In the original publication of this article [1], there is a mistake in Fig. 4E.

    Authors: Qianqian Liu, Hongye Ma, Xiuhua Sun, Bing Liu, Yang Xiao, Shimeng Pan, Huimin Zhou, Weijie Dong and Li Jia
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:357

    The original article was published in Journal of Experimental & Clinical Cancer Research 2019 38:199

  29. Long noncoding RNAs (lncRNAs) have been reported to be associated with the proliferation of several cancer cells. The aim of this study was to investigate the role of FLVCR1-AS1 in ovarian serous cancer (OSC).

    Authors: Huan Yan, Hong Li, Maria A. Silva, Yichun Guan, Li Yang, Linlin Zhu, Zhan Zhang, Genxia Li and Chenchen Ren
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:356
  30. Human epidermal growth factor receptor 2 (HER2) is overexpressed in multiple cancers, which is associated with poor prognosis. Herceptin and other agents targeting HER2 have potent antitumor efficacy in patien...

    Authors: Shengnan Yu, Jing Zhang, Yongxiang Yan, Xudong Yao, Lijuan Fang, Hui Xiong, Yang Liu, Qian Chu, Pengfei Zhou and Kongming Wu
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:355
  31. Estrogen receptor β (ERβ) has been reported to play an anti-cancer role in breast cancer, but the regulatory mechanism by which ERβ exerts this effect is not clear. Claudin-6 (CLDN6), a tight junction protein,...

    Authors: Peiye Song, Yanru Li, Yuan Dong, Yingying Liang, Huinan Qu, Da Qi, Yan Lu, Xiangshu Jin, Yantong Guo, Yiyang Jia, Xinqi Wang, Wenhong Xu and Chengshi Quan
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:354
  32. Tubeimoside-I (TBM), a plant-derived bioactive compound, shows antitumor activity in different tumors and can enhance the efficacy of chemotherapeutic agents. However, the detail mechanism underlying remains t...

    Authors: Jianghong Yan, Xiaoyun Dou, Jing Zhou, Yuanfeng Xiong, Ling Mo, Longhao Li and Yunlong Lei
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:353
  33. In the original publication of this article [1], the author’ affiliations need to be revised, because the first and second affiliations should combine as the same affiliation.

    Authors: Haoming Mai, Bin Zhou, Li Liu, Fu Yang, Carly Conran, Yuan Ji, Jinlin Hou and Deke Jiang
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:352

    The original article was published in Journal of Experimental & Clinical Cancer Research 2019 38:198

  34. Soluble fibrinogen-like protein 2 (sFGL2), a secretory protein expressed by regulatory T cells (Tregs) with immunosuppressive activity, is highly expressed in both the peripheral blood and tumor tissue of pati...

    Authors: Muyang Yang, Zhongwei Zhang, Jiajia Chen, Mengying Xu, Jiaquan Huang, Ming Wang, Weina Li, Xiaoyang Wan, Man-Fung Yuen, Xiaoping Luo, Dong Xi and Qin Ning
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:351
  35. Ubiquitin E3 ligase CUL4A plays important oncogenic roles in the development of cancers. DTL, one of the CUL4-DDB1 associated factors (DCAFs), may involve in the process of cancer development. Programmed cell ...

    Authors: Haoran Cui, Qin Wang, Zhenchuan Lei, Maoxiao Feng, Zhongxi Zhao, Yunshan Wang and Guangwei Wei
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:350
  36. Over the past decade, newly designed cancer therapies have not significantly improved the survival of patients diagnosed with Malignant Pleural Mesothelioma (MPM). Among a limited number of genes that are freq...

    Authors: Claudio Pulito, Etleva Korita, Andrea Sacconi, Mariacristina Valerio, Luca Casadei, Federica Lo Sardo, Federica Mori, Maria Ferraiuolo, Giuseppe Grasso, Anna Maidecchi, Jacopo Lucci, Marius Sudol, Paola Muti, Giovanni Blandino and Sabrina Strano
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:349
  37. Ten-eleven translocation 1 (TET1) is a dioxygenase that converts 5-methylcytosine (5-mC) to 5-hydroxymethylcytosine (5-hmC) to induce DNA demethylation. TET1 has been reported to be absent in cancers, and to i...

    Authors: Jian Wu, Hongzhe Li, Minmin Shi, Youwei Zhu, Yang Ma, Yiming Zhong, Cheng Xiong, Hao Chen and Chenghong Peng
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:348
  38. Pancreatic cancer is a highly lethal malignancy with poor prognosis. Anillin (ANLN), an actin binding protein, is upregulated and plays an important role in many malignant tumors. However, the precise role of ...

    Authors: Anbin Wang, Haisu Dai, Yi Gong, Chengcheng Zhang, Junjie Shu, Yuandeng Luo, Yan Jiang, Wei Liu and Ping Bie
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:347
  39. RUNX2 is a Runt-related transcription factor required during embryogenesis for skeletal development and morphogenesis of other organs including thyroid and breast gland. Consistent evidence indicates that RUNX...

    Authors: Gloria Manzotti, Federica Torricelli, Benedetta Donati, Valentina Sancisi, Mila Gugnoni and Alessia Ciarrocchi
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:346
  40. Epithelial ovarian cancer (EOC) is the malignant tumor of the female reproductive system with the highest fatality rate. Tolerance of chemotherapeutic drugs like cisplatin (DDP) occurring in very early stage i...

    Authors: Xiaoran Long, Keqi Song, Hao Hu, Qi Tian, Wenjing Wang, Qian Dong, Xia Yin and Wen Di
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:345
  41. Accumulated evidences have demonstrated that long non-coding RNAs (lncRNAs) are dysregulated and correlate with the pathophysiological basis of malignant tumors. The objective of this research is to uncover th...

    Authors: Chen Qi, Chen Xiaofeng, Li Dongen, Yang Liang, Xu Liping, Hu Yue and Jiang Jianshuai
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:344
  42. Kidney Renal Clear Cell Carcinoma (KIRC) accounts for 75% of all renal cancers. Previous study had conflict evidences regarding NR1B2 role in cancer, and its expression and biological role in KIRC remained unc...

    Authors: Lei Yin, Wenjia Li, Guangchun Wang, Heng Shi, Keyi Wang, Huan Yang and Bo Peng
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:343
  43. Androgen receptor (AR)-targeted treatments improve the survival of castration-resistant prostate cancer (CRPC) patients; however, secondary resistance to these agents ultimately occurs in virtually all patient...

    Authors: Sahyun Pak, Sejun Park, Yunlim Kim, Jung-Hyuck Park, Chan-Hee Park, Kyoung-June Lee, Choung-soo Kim and Hanjong Ahn
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:342

    The Correction to this article has been published in Journal of Experimental & Clinical Cancer Research 2019 38:440

  44. Prostate tumor over expressed gene 1 (PTOV1) has been reported as an oncogene in several human cancers. However, the clinical significance and biological role of PTOV1 remain elusive in non-small cell lung can...

    Authors: Zhiqiang Wu, Zhuang Liu, Xiangli Jiang, Zeyun Mi, Maobin Meng, Hui Wang, Jinlin Zhao, Boyu Zheng and Zhiyong Yuan
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:341
  45. Pancreatic ductal adenocarcinoma is one of the most aggressive cancers, with a 5-year survival rate of less than 8%. The complicated tumor microenvironment, particularly TGF-β, provides possible convenience fo...

    Authors: Ruizhi He, Min Wang, Chunle Zhao, Ming Shen, Yahong Yu, Li He, Yan Zhao, Hua Chen, Xiuhui Shi, Min Zhou, Shutao Pan, Yuhui Liu, Xingjun Guo, Xu Li and Renyi Qin
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:340
  46. Glioma initiating cells (GICs), also known as glioma stem cells (GSCs), play an important role in the progression and recurrence of glioblastoma multiforme (GBM) due to their potential for self-renewal, multip...

    Authors: Li Yi, Xingchen Zhou, Tao Li, Peidong Liu, Long Hai, Luqing Tong, Haiwen Ma, Zhennan Tao, Yang Xie, Chen Zhang, Shengping Yu and Xuejun Yang
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:339
  47. The GKN2 is a secretory protein, whose levels decrease in gastric cancer. The present study aimed to investigate the expression, function and mechanism of action of GKN2 in gastric cancer.

    Authors: Ziqiang Zhang, Hongyuan Xue, Yuanqiang Dong, Jun Zhang, Yida Pan, Liubin Shi, Panpan Xiong, Jie Zhu, Wenshuai Li, Wanwei Zheng, Jie Liu and Jianjun Du
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:338
  48. Metabolic rewiring is a common feature of many cancer types, including prostate cancer (PCa). Alterations in master genes lead to mitochondrial metabolic rewiring and provide an appealing target to inhibit can...

    Authors: Jiaxin Fan, Yanru Fan, Xiao Wang, Lingfang Niu, Limei Duan, Jinxiao Yang, Luo Li, Yingying Gao, Xiaohou Wu and Chunli Luo
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:337
  49. Pancreatic Ductal Adenocarcinoma (PDAC) is an aggressive and lethal disease, lacking effective therapeutic approaches. Available therapies only marginally prolong patient survival and are frequently coupled wi...

    Authors: Aleksandra Adamska, Alice Domenichini, Emily Capone, Verena Damiani, Begum Gokcen Akkaya, Kenneth J. Linton, Pierluigi Di Sebastiano, Xi Chen, Adam B. Keeton, Veronica Ramirez-Alcantara, Yulia Maxuitenko, Gary A. Piazza, Vincenzo De Laurenzi, Gianluca Sala and Marco Falasca
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:312
  50. In the original publication of this article [1], the authors reported the order of the authors was incorrect and needs to be revised. The original article has been updated to rectify this error.

    Authors: Qing Yang, Binhui Xie, Hui Tang, Wei Meng, Changchang Jia, Xiaomei Zhang, Yi Zhang, Jianwen Zhang, Heping Li and Binsheng Fu
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:336

    The original article was published in Journal of Experimental & Clinical Cancer Research 2019 38:263

Annual Journal Metrics

  • 2022 Citation Impact
    11.3 - 2-year Impact Factor
    11.5 - 5-year Impact Factor
    1.870 - SNIP (Source Normalized Impact per Paper)
    2.413 - SJR (SCImago Journal Rank)

    2023 Speed
    4 days submission to first editorial decision for all manuscripts (Median)
    100 days submission to accept (Median)

    2023 Usage 
    3,003,080 downloads
    3,022 Altmetric mentions